CVS Health Corporation (NYSE:CVS) is one of the Most Undervalued Stocks to Buy According to Analysts. On March 12, Bernstein analyst Lance Wilkes upgraded the company’s stock to “Outperform” from “Market Perform” with a price objective of $94, an increase from the prior target of $91. This upgrade demonstrates CVS Health Corporation (NYSE:CVS)’s attractive exposure to the Medicare Advantage turnaround and expectations of stable earnings in the pharmacy and pharmacy benefit manager businesses after the reforms.

According to the analyst, the PBM bill passage and the first Federal Trade Commission settlement with Cigna act as the clearing event for the company’s stock.

In a different update, CVS Health Corporation (NYSE:CVS) and Google Cloud announced a strategic partnership, targeting the reimagining of health care experiences, increasing consumer engagement, and helping better health outcomes. The company’s launch of Health100, which is a health technology services subsidiary, remains central to this partnership. With Health100, the company offers the future of agentic, AI-powered health care.

CVS Health Corporation (NYSE:CVS), a diversified healthcare company, combines insurance, pharmacy benefit management, retail pharmacies, and clinical services to provide integrated healthcare solutions throughout the United States via its vertically integrated platform.

While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.